UnknownPhase 3NCT00379457
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma
Studying Alveolar rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Paediatric Soft Tissue Sarcoma Study Group
- Principal Investigator
- Gianni Bisogno, MDAzienda Ospedaliera di Padova
- Intervention
- dactinomycin(biological)
- Enrollment
- 600 enrolled
- Eligibility
- 20 years · All sexes
- Timeline
- 2006
Study locations (27)
- St. Anna Children's Hospital, Vienna, Austria
- Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
- Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland
- Vall d'Hebron University Hospital, Barcelona, Spain
- Uppsala University Hospital, Uppsala, Sweden
- University Children's Hospital, Zurich, Switzerland
- Birmingham Children's Hospital, Birmingham, England, United Kingdom
- Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
- Addenbrooke's Hospital, Cambridge, England, United Kingdom
- Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
- Leicester Royal Infirmary, Leicester, England, United Kingdom
- Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
- Middlesex Hospital, London, England, United Kingdom
- Great Ormond Street Hospital for Children, London, England, United Kingdom
- +12 more locations on ClinicalTrials.gov
Collaborators
Italian Association for Pediatric Hematology Oncology · Children's Cancer and Leukaemia Group · Dutch Childhood Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00379457 on ClinicalTrials.govOther trials for Alveolar rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05304585Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05071209Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT04994132A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaChildren's Oncology Group
- RECRUITINGPHASE3NCT06669013Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasN.N. Petrov National Medical Research Center of Oncology
- ACTIVE NOT RECRUITINGNCT03296371Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02567435Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT00077285Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk RhabdomyosarcomaMemorial Sloan Kettering Cancer Center